Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
7.40
-0.23 (-3.01%)
May 6, 2025, 9:50 AM EDT - Market open
Arvinas Revenue
Arvinas had revenue of $188.80M in the quarter ending March 31, 2025, with 646.25% growth. This brings the company's revenue in the last twelve months to $426.90M, up 498.74% year-over-year. In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth.
Revenue (ttm)
$426.90M
Revenue Growth
+498.74%
P/S Ratio
1.29
Revenue / Employee
$992,791
Employees
430
Market Cap
540.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
ARVN News
- 23 hours ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out - Accesswire
- 1 day ago - Arvinas: Yet Another Biotech Trading Below Net Cash, But It's Only A Mild Bull Case - Seeking Alpha
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Stockholders to Connect - Accesswire
- 3 days ago - Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 4 days ago - Arvinas, Inc. (ARVN) Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation - Accesswire
- 4 days ago - Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 days ago - Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 - GlobeNewsWire